Paratek Pharmaceuticals Inc (NASDAQ:PRTK) – Equities researchers at G.Research boosted their FY2019 earnings per share estimates for Paratek Pharmaceuticals in a research report issued to clients and investors on Thursday, August 8th. G.Research analyst K. Kedra now forecasts that the specialty pharmaceutical company will earn ($4.40) per share for the year, up from their prior estimate of ($4.55). G.Research also issued estimates for Paratek Pharmaceuticals’ FY2020 earnings at ($4.15) EPS, FY2021 earnings at ($2.85) EPS, FY2022 earnings at ($0.95) EPS and FY2023 earnings at $0.35 EPS.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.14. Paratek Pharmaceuticals had a negative net margin of 597.22% and a negative return on equity of 459.96%. The company had revenue of $2.05 million during the quarter, compared to the consensus estimate of $1.86 million.
Several other research analysts also recently issued reports on PRTK. HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, June 26th. Wedbush restated an “outperform” rating and set a $12.00 price objective (down from $17.00) on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. ValuEngine upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating and set a $4.75 price objective for the company in a research report on Friday, August 9th. Finally, LADENBURG THALM/SH SH restated a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $17.25.
PRTK stock opened at $4.46 on Monday. The firm’s 50 day moving average is $3.68. Paratek Pharmaceuticals has a 12-month low of $2.87 and a 12-month high of $12.20. The company has a debt-to-equity ratio of 14.48, a quick ratio of 11.83 and a current ratio of 12.17. The firm has a market cap of $144.49 million, a P/E ratio of -1.25 and a beta of 1.81.
Institutional investors have recently modified their holdings of the stock. Water Island Capital LLC raised its position in shares of Paratek Pharmaceuticals by 15.1% during the 1st quarter. Water Island Capital LLC now owns 366,648 shares of the specialty pharmaceutical company’s stock worth $1,965,000 after purchasing an additional 48,130 shares during the last quarter. Trellus Management Company LLC raised its position in shares of Paratek Pharmaceuticals by 65.0% during the 2nd quarter. Trellus Management Company LLC now owns 165,000 shares of the specialty pharmaceutical company’s stock worth $658,000 after purchasing an additional 65,000 shares during the last quarter. Deutsche Bank AG raised its position in shares of Paratek Pharmaceuticals by 16.9% during the 4th quarter. Deutsche Bank AG now owns 316,661 shares of the specialty pharmaceutical company’s stock worth $1,624,000 after purchasing an additional 45,777 shares during the last quarter. Norges Bank acquired a new position in shares of Paratek Pharmaceuticals during the 4th quarter worth approximately $2,447,000. Finally, BNP Paribas Arbitrage SA acquired a new position in shares of Paratek Pharmaceuticals during the 1st quarter worth approximately $36,000. Hedge funds and other institutional investors own 73.12% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Further Reading: Management Fee
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.